Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA

This article was originally published in The Tan Sheet

Executive Summary

The possibility of working with FDA on dietary supplement regulation/policy was a topic slated for discussion at the annual strategic planning session of the PhRMA board meeting in Chantilly, Va. Nov. 11-12. It appears the trade group sees supplement regulation as a possible common ground on which to build future relations with the agency. Although a handful of PhRMA members market supplement products in the U.S., the majority may look favorably upon an organized effort to squelch supplement claims or increase enforcement actions allowed under DSHEA. Maneuvering could be tricky, however, as one of PhRMA's primary supporters on Capitol Hill - Sen. Orrin Hatch (R-Utah) -also is a staunch advocate of dietary supplements

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel